Trending stocks

Sino Biopharmaceutical Ltd EBITDA jumped on 25.3% in 2015 and EBITDA Margin increased slightly on 1.4 pp from 21.4% to 22.8%

30/03/2016 • About Sino Biopharmaceutical Ltd ($1177) • By InTwits

Sino Biopharmaceutical Ltd reported 2015 financial results today. Overall the company's long term financial model is characterised by the following facts:
  • Sino Biopharmaceutical Ltd is a fast growth stock: 2015 revenue growth was 17.5%, 5 year revenue CAGR was 28.9% at 2015 ROIC 26.2%
  • Sino Biopharmaceutical Ltd has medium CAPEX intensity: 5 year average CAPEX/Revenue was 5.0%. At the same time it's a lot of higher than industry average of 4.6%.
  • CAPEX is quite volatile: 753 in 2015, 610 in 2014, 563 in 2013, 332 in 2012, 286 in 2011
  • The company has highly profitable business model: ROIC is at 26.2%
Below you can find a comprehensive analysis of the key data driving the company's performance and stock price.

Sino Biopharmaceutical Ltd ($1177) key annual financial indicators

mln. HKD201120122013201420152015/2014
P&L
Revenue5,7827,4979,90112,37814,55017.5%
Gross Profit4,5395,8867,6739,45811,30119.5%
SG&A3,0543,9935,0526,1677,13115.6%
EBITDA1,0871,6032,0042,6513,32225.3%
Net Income4638911,0371,5131,77917.5%
Balance Sheet
Cash2,0182,4952,8903,1672,531-20.1%
Short Term Debt5121744351,420226.3%
Long Term Debt352001,289306-76.2%
Cash flow
Capex28633256361075323.4%
Ratios
Revenue growth41.5%29.7%32.1%25.0%17.5%
EBITDA growth-5.8%47.4%25.0%32.3%25.3%
Gross Margin78.5%78.5%77.5%76.4%77.7%1.3%
EBITDA Margin18.8%21.4%20.2%21.4%22.8%1.4%
Net Income Margin8.0%11.9%10.5%12.2%12.2%-0.0%
SG&A, % of revenue52.8%53.3%51.0%49.8%49.0%-0.8%
CAPEX, % of revenue4.9%4.4%5.7%4.9%5.2%0.2%
ROIC19.9%26.2%26.8%26.5%26.2%-0.3%
ROE12.4%21.2%20.6%25.0%24.8%-0.3%
Net Debt/EBITDA-1.8x-1.5x-1.4x-0.5x-0.2x0.3x

Revenue and profitability


The company's Revenue jumped on 17.5% in 2015. Despite revenue decline the EBITDA margin expanded. EBITDA Margin surged on 15.6 pp from 3.5% to 19.1% in 2015.

Gross Margin increased slightly on 1.3 pp from 76.4% to 77.7% in 2015. SG&A as a % of Revenue decreased slightly on 0.81 pp from 49.8% to 49.0% in 2015.

Net Income marign showed almost no change in 2015.

Capital expenditures (CAPEX) and working capital investments


In 2015 Sino Biopharmaceutical Ltd had CAPEX/Revenue of 5.2%. CAPEX/Revenue increased slightly on 0.75 pp from 4.4% in 2012 to 5.2% in 2015. It's average CAPEX/Revenue for the last three years was 5.3%.

Return on investment


The company operates at high and attractive ROIC (26.18%) and ROE (24.76%). ROIC showed almost no change in 2015. ROE showed almost no change in 2015.

Leverage (Debt)


Debt level is -0.2x Net Debt / EBITDA and 0.5x Debt / EBITDA. Net Debt / EBITDA surged on 0.3x from -0.5x to -0.2x in 2015. Debt showed almost no change in 2015 while cash dropped on 20.1% in 2015.

Appendix 1: Peers in Pharmaceuticals


Below you can find Sino Biopharmaceutical Ltd benchmarking vs. other companies in Pharmaceuticals industry. It's shown for the period of 5 years for the key financial metrics. Each table has median value for all the companies in the industry together with individual financial data of the top-5 companies in the industry by particular financial metric.

Top companies by Revenue growth, %

Top 5 FY2011 FY2012 FY2013 FY2014 FY2015
China Health Group Inc ($8225)58.5%-48.0%-60.1%244.1%
Wai Yuen Tong Medicine Holdings Ltd ($897)-9.9%45.9%-10.5%105.6%
Oriental Unicorn Agricultural Group Ltd ($8120)30.2%-78.1%16.8%100.8%
China Traditional Chinese Medicine Co Ltd ($570)22.3%35.2%90.0%40.0%
Shandong Luoxin Pharmaceutical Group Stock Co Ltd ($8058)37.0%13.5%9.4%30.5%
 
Median (38 companies)7.4%14.3%13.5%15.3%3.3%
Sino Biopharmaceutical Ltd ($1177)29.7%32.1%25.0%17.5%


Top companies by Gross margin, %

Top 5 FY2011 FY2012 FY2013 FY2014 FY2015
Luye Pharma Group Ltd ($2186)83.0%83.5%83.6%81.0%81.4%
Consun Pharmaceutical Group Ltd ($1681)75.5%75.7%79.1%78.3%80.7%
Jilin Province Huinan Changlong Bio-pharmacy Co Ltd ($8049)83.9%82.0%81.5%80.9%79.9%
China Health Group Inc ($8225)38.7%43.4%33.6%76.2%75.7%
Sihuan Pharmaceutical Holdings Group Ltd ($460)76.5%75.2%56.3%68.5%70.3%
 
Median (37 companies)38.0%39.1%37.2%48.7%49.9%
Sino Biopharmaceutical Ltd ($1177)78.5%78.5%77.5%76.4%77.7%


Top companies by EBITDA margin, %

Top 5 FY2011 FY2012 FY2013 FY2014 FY2015
Northeast Tiger Pharmaceutical Corp Ltd ($8197)132.2%193.8%205,840.0%-15,344.8%49,650.0%
Sihuan Pharmaceutical Holdings Group Ltd ($460)48.4%38.8%65.4%70.9%93.3%
Hua Han Bio-Pharmaceutical Holdings Ltd ($587)32.9%60.6%21.0%28.8%61.1%
U-Home Group Holdings Ltd ($2327)23.9%9.8%-16.6%-46.7%51.7%
Beijing Tong Ren Tang Chinese Medicine Co Ltd ($8138)29.7%41.3%45.4%47.5%49.1%
 
Median (38 companies)17.0%18.7%19.7%21.4%20.0%
Sino Biopharmaceutical Ltd ($1177)18.8%21.4%20.2%21.4%22.8%


Top companies by CAPEX/Revenue, %

Top 5 FY2011 FY2012 FY2013 FY2014 FY2015
Hao Wen Holdings Ltd ($8019)6.4%30.0%2.3%38.2%44.8%
Hua Han Bio-Pharmaceutical Holdings Ltd ($587)3.8%0.9%1.4%7.6%40.5%
Lee's Pharmaceutical Holdings Ltd ($950)8.5%18.6%20.9%7.1%26.1%
Tianda Pharmaceuticals Ltd ($455)4.8%6.0%3.9%10.5%24.4%
Lijun International Pharmaceutical Holding Co Ltd ($2005)19.5%16.8%52.4%39.6%18.7%
 
Median (37 companies)10.9%8.3%9.7%7.6%4.4%
Sino Biopharmaceutical Ltd ($1177)4.9%4.4%5.7%4.9%5.2%


Top companies by ROIC, %

Top 5 FY2011 FY2012 FY2013 FY2014 FY2015
Beijing Tong Ren Tang Chinese Medicine Co Ltd ($8138)25.3%27.5%23.8%25.9%
Sihuan Pharmaceutical Holdings Group Ltd ($460)14.3%13.7%18.3%22.0%25.4%
Dawnrays Pharmaceutical Holdings Ltd ($2348)17.7%12.6%14.0%17.8%23.5%
Lee's Pharmaceutical Holdings Ltd ($950)31.3%26.1%22.0%22.4%22.7%
CSPC Pharmaceutical Group Ltd ($1093)9.9%14.5%12.8%18.1%21.7%
 
Median (39 companies)8.5%12.2%9.3%11.1%10.1%
Sino Biopharmaceutical Ltd ($1177)19.9%26.2%26.8%26.5%26.2%


Top companies by Net Debt / EBITDA

Top 5 FY2011 FY2012 FY2013 FY2014 FY2015
Northeast Tiger Pharmaceutical Corp Ltd ($8197)2.2x2.3x3.7x22.2x
U-Home Group Holdings Ltd ($2327)3.3x10.1x9.9x
Lansen Pharmaceutical Holdings Ltd ($503)0.9x1.7x2.8x3.4x4.7x
China Grand Pharmaceutical and Healthcare Holdings Ltd ($512)2.5x5.4x4.0x3.4x4.3x
United Laboratories International Holdings Ltd/The ($3933)4.4x6.5x4.6x4.2x4.0x
 
Median (31 companies)-0.4x0.0x-0.2x-0.6x-0.4x
Sino Biopharmaceutical Ltd ($1177)-1.8x-1.5x-1.4x-0.5x-0.2x